See this page online at: http://www.bioscienceworld.ca/BestPractices
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
February 22 2011
British Columbia company OncoGenex included in Fast Company Magazine's Top Ten "Most Innovative Companies" in the biotech Industry BC-based OncoGenex Pharmaceuticals, Inc. has been named as one of the top ten companies in the biotech industry in the March 2011 issue of Fast Company, as part of the magazine's annual list of the "Most Innovative Companies."
|
|
February 16 2011
New centres of excellence share $61M in funding Five new Centres of Excellence for Commercialization and Research (CECR) have been established and are sharing a total of $61.1 million in funding from the federal government over the next five years.
|
|
January 24 2011
PwC and BIOTECanada: Life sciences survey shows industry wants government to step up its support A Canadian life sciences forecast published by PwC and BIOTECanada shows that survey participants are counting on more government support at a time when funding is hard to find.
|
|
October 14 2010
New family medicine training centre opens in Peterborough, ON In an effort to help attract family doctors to Peterborough, ON and Kawartha, ON, Queen’s family medicine residency program is expanding to the area.
|
|
July 07 2010
Investors dump Stem Cell Therapeutics amid disappointing trial of stroke drug Shares of Stem Cell Therapeutics tumbled after the Calgary research firm said it still can't explain definitively why its drug didn't do better than a placebo in a recent trial and announced that it was letting go of its senior staff.
|
|
June 22 2010
National team of industry leaders to work together to strengthen Canada’s bioeconomy At its 2010 annual general meeting in Montreal, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.
|
|
June 22 2010
2010 Canadian Science Policy conference to take place in Montréal The Canadian Science Policy Centre has announced the date and themes of its annual conference, as well as issued calls for sponsors and abstracts.
|
|
May 17 2010
Crossroad for BioTransfer takes its show on the road The Crossroad for BioTransfer is back, with a new twist. The third edition of this made-in-Montreal event, which brings together business people and leading scientific researchers, will be held this week (May 18) in Boston.
|
|
May 17 2010
New funding for bioscience companies in Ontario A new commercialization strategy providing access to an initial round of special financing from the Government of Ontario will help the province’s bioscience companies fund advancement of their programs to treat, prevent and diagnose disease. Ontario spends more than $5 billion a year on drug therapies and devices, most of which are imported.
|
|
April 30 2010
Biotech industry showing resilience despite challenging conditions: Ernst & Young Canada's biotech industry has not only survived the global economic crisis, but finished 2009 with a large increase in revenue and significantly reduced losses, due in part to significant cost-cutting measures, according to Beyond borders, Ernst & Young's annual global biotechnology report.
|
|
April 21 2010
Allon adopts shareholder rights plan Allon Therapeutics Inc. board of directors has approved in principle the adoption of a shareholder rights plan agreement.
|
|
April 20 2010
Winners announced in Biotechnology Venture Challenge The Sanofi Pasteur Healthcare and Biotechnology Venture Challenge, organized by YORKbiotech and the Schulich School of Business at York University, announced its 2009 winners on March 1, 2010.
|
|
April 16 2010
The Biotechnology Initiative rebrands itself as Life Sciences Ontario The Biotechnology Initiative (TBI), operating in its 20th year, announced major changes following the approval by members at its annual meeting held April 8, 2010 in Toronto. TBI will now be called Life Sciences Ontario (LSO) thereby enabling the organization through an expanded mandate, to serve members needs across Ontario particularly public policy and government relations.
|
|
March 26 2010
Prion Institute announces International Young Researcher Prize The Alberta Prion Research Institute is recognizing young researchers in prion science by offering a one-time $25,000 prize to be awarded in 2010. The International Young Researcher Prize marks five years since the Prion Institute was created to address issues to do with prion and neurological protein mis-folding diseases.
|
|
March 12 2010
Budget announcement sees removal of tax barriers and opens door to flow of foreign capital for biotech Removing administrative barriers under the Canada-US Tax Treaty for investors such as non-resident venture capital funds are a welcome change in this year’s budget announcement, and they should ease the way for investment in Canadian biotechnology firms according to trade industry association BIOTECanada.
|
|
March 09 2010
Budget announcement sees removal of tax barriers and opens door to flow of foreign capital for biotech Removing administrative barriers under the Canada-US Tax Treaty for investors such as non-resident venture capital funds are a welcome change in this year’s budget announcement, and they should ease the way for investment in Canadian biotechnology firms according to trade industry association BIOTECanada.
|
|
February 19 2010
New award focuses on colorectal or prostate cancer The Canadian Radiation Oncology Foundation and sanofi-aventis have announced the creation of a new award for colorectal or prostate cancer research.
|
|
January 26 2010
Koenig & Consultants launch CELL management study: An exploration into Canadian excellence in leadership in life sciences As the good people of ABBA sang “Money! Money! Money!”. Yes, it’s on all our minds. But underneath this, the question remains, who does get the little money that’s trickling in?
|
|
January 08 2010
Med BioGene files for US IPO Canadian personalized diagnostics firm Med BioGene has filed for an initial public offering in the US.
|
|
December 18 2009
New Tandem fund expands options for cash-strapped biotech industry According to BIOTEC Canada, the recently announced Tandem fund of $300 million presents a much-needed financing option for Canada’s biotechnology industry.
|
|
December 03 2009
New Canadian research network aims to build a better eye A network of 12 university researchers and 10 industry partners are the recipients of more than $6.7-million in funding to develop and commercialize new materials and technologies to treat the nearly one-million Canadians suffering from vision loss, a number expected to dramatically increase as Canada’s population ages.
|
|
November 25 2009
Biomedical centres to foster commercialization Two new biomedical centres at the University of Calgary have been established to accelerate development of innovative medical technology in Alberta. Federal and provincial governments, research funding agencies and the University of Calgary are partnering to create the new centres to foster innovation and commercialization of biomedical technologies.
|
|
November 25 2009
BDC provides $57 million in financing for Hamilton-area R & D project The Business development Bank of Canada (BDC) announces that it is contributing $57 million under the federal government's Business Credit Availability Program towards McMaster Innovation Park's new $69 million research complex.
|
|
November 25 2009
Canadian companies optimistic about going public - KPMG Sixty per cent of Canadian executives surveyed expect the Canadian IPO market to increase in the next 6 to 12 months, with one-third expecting it to remain the same, according to a newly-released KPMG survey.
|
|
October 07 2009
TBI launches mentorship program The Biotechnology Initiative successfully launched its mentorship program at the TBI Breakfast Meeting on Sept. 17, 2009. The program was created to address identified gaps in the biotech industry related to human capital, and bridge science and business.
|
|
September 22 2009
Canadians see biotech as crucial to economic future Annual opinion polling results shows overwhelming support for biotechnology as National Biotechnology Week celebrates the industry across Canada.
|
|
September 10 2009
New life science support organization created LOM BioQuest aims to provide Canadian life-sciences companies with the home-grown support the industry is missing.
|
|
September 08 2009
BIOTECanada's blueprint document, Beyond Moose and Mountains: In light of this theme, we thought it would be appropriate to revisit Beyond Moose and Mountains, BIOTECanda’s blueprint on how to build the world’s leading bio-based economy which was released to the public in May.
|
|
September 03 2009
Promoting Bioscience education across Canada The Canadian Biotechnology Education Resource Centre (CBERC) is changing its name to Bioscience Education Canada (BEC) in recognition of the expanding role of biotechnology in many fields of biological science. Under its new operating name, the national non-profit charitable organization will continue its mandate to improve the quality of bioscience education in Canadian schools and encourage more young Canadians to pursue studies and careers of Canada’s growing bioeconomy.
|
|
July 14 2009
U of O scientists win $1.6 million grant Two groups of scientists at the University of Ottawa were handed 20 grants of $1.6 million each from the government of Canada in an effort to help train the next generation of scientists as managers.
|
|
February 18 2009
Canadian biotech jobs and innovation at risk as 50% of firms report cash shortage BIOTECanada renewed its call for the federal government to support innovation in the upcoming federal budget, highlighting the strong contribution of life sciences to Canada’s research and discovery infrastructure.
|
|
August 24 2007
Allon named "Top 10" partnering candidate by expert conference Allon Therapeutics Inc. Alzheimer's program has been selected as one of the top ten not yet partnered biotech programs in the world.
|
|
August 24 2007
Transition Therapeutics Files Registration Statement for Potential NASDAQ Listing Transition Therapeutics Inc. announces the filing of a Registration Statement on Form 40-F in connection with the filing of its listing application for the NASDAQ Stock Market.
|
|
May 04 2007
MIHR and PIPRA to launch handbook of best practices for intellectual property management The Centre for the Management of Intellectual Property in Health Research & Development (MIHR) and the Public Intellectual Property Resource for Agriculture (PIPRA) formally launch the results of its recent and intensive collaboration: Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices at this week's Bio International Convention, held in Boston.
|
|
March 12 2007
How To Get The Money Flowing From A VC For many biotechnology start-ups, venture capital investment is the lifeblood that sustains the company through the early years of product and patent portfolio development.
|
|
February 01 2007
Asked & Answered By Dave Howlett Dave Howlett is VP corporate development in Life Sciences at the MAGNES Group in Oakville, ON. He has presented his signature lecture series 'Knocking down Silos' to numerous companies, associations and universities in the biotech sector. Please see www.davehowlett.com for more information.
|
|
January 10 2007
Pathology Service Enhancement By Brian A. Schaefer, D. Phil Moving Expertise from the Laboratory to the Point of Care Throughout the last decade Drs. Smith and McNeely have conducted research aimed at improving clinical laboratory utilisation. This research has produced a technology that has been shown to have dramatic implications for clinical laboratories, patient care and healthcare economics. |
|
November 27 2006
Study finds standard resection performed over surgery A study of 8,380 patients from the Surveillance, Epidemiology and End Results registry has found that only one-third of patients who underwent surgical resection for locally advanced colorectal cancer received a multivisceral resection, a procedure recommended by the National Cancer Institute and American Society of Colon and Rectal Surgeons.
|
|
November 27 2006
New radiation technique reduces breast skin burns A new study demonstrates that delivering better radiation technique through breast intensity modulated radiation therapy (BIMRT) improves treatment tolerance and quality of life for patients.
|
|
November 27 2006
Miraculins targets gastric cancer test Miraculins Inc. has begun verifying gastric cancer biomarkers identified in an earlier discovery phase study in the hopes of finding a simple blood-based test for gastric cancer.
|
|
November 07 2006
Gowlings releases essential guide to life sciences law in Canada Gowling Lafleur Henderson LLP (Gowlings) and publisher Thomson Carswell have released Life Sciences Law in Canada, the first comprehensive guide to complex Canadian life sciences laws.
|
|
November 02 2006
Ecopia BioSciences Inc. has received a No Objection Letter Ecopia BioSciences Inc. has received a No Objection Letter from the Therapeutics Products Directorate of Health Canada.
|
|
October 24 2006
A shot in the arm for VIDO The federal government is putting $1.75 million into the University of Saskatchewans Vaccine and Infectious Disease Organization (VIDO), three years worth of funding dedicated to developing alternatives to antibiotics.
|
|
October 24 2006
Canadian Companies Dominate North Americas Technology Industry Canada is home to fully half of the top 10 technology firms on the continent, with growth that is more than double that of their American counterparts, according to ranking and highest revenue growth in North America according to the 2006 roundup of fastest growing assembled by Deloitte.
|
|
October 24 2006
Attitude affects womens math performance University of British Columbia researchers have explored the question of how a perception of genetic causes for womens ability to do mathematics can influence how well women do on mathematical tests
|
|
October 02 2006
Program Connects Students to Biotech A Manitoba program that connects teachers and students to the science of biotechnology has received a $150,000 US grant from the Monsanto Fund.
|
|
October 02 2006
Toxin Alert Receives U.S. Government Support The University of Southern Mississippi received a $1-million US award from the National Oceanographic and Atmospheric Administration to begin commercialization of Toxin Alert Inc.'s Toxin Guard biosensor system in Mississippi.
|
|
September 13 2006
Sigma, Oxford Sue Open Biosystems Sigma-Aldrich Corp. and Oxford BioMedica, a spinoff from Oxford University, have filed a lawsuit against Open Biosystems Inc.
|
|
September 12 2006
Miraculins Expands Pipeline Winnipeg-based Miraculins Inc. is planning on expanding its product pipeline to include new diagnostic research programs for pancreatic and stomach cancer.
|
|
September 11 2006
Theralase Builds Sports Specialty Theralase Technologies Inc. has named Dr. James R. Andrews as chairman of its newly organized medical and scientific advisory board.
|
|
September 11 2006
Cost-CuttingMeasuresAtMedMira Halifax-based MedMira Inc. is implementing cost-containment initiatives intended to reduce operating expenses by 33 per cent.
|
|
September 11 2006
You Can't Win Them All Making everyone happy with Bill 102 is proving tricky for the Ontario government, despite the widespread feeling that something needs to be done to fix the current system.
|
|
September 08 2006
Court Rules Against Biovail Patent A California judge has ruled that Anchen Pharmaceutical Inc.'s planned generic version of Wellbutrin XL® does not infringe on Biovail Corp.'s patent.
|
|
September 08 2006
Ontario Program Address Critical Startup Needs The Ontario government has launched its Market Readiness Program, part of the $160-million Ideas to Market strategy announced in the 2006 budget.
|
|
August 10 2006
MDX Changes Name to Reflect Core Business Vancouver-based MDX Medical Inc. has a new name. In June, the company change its moniker to Urodynamix Technologies Ltd. to reflect its focus on urology, bladder diagnostics and monitoring solutions.
|
|
August 10 2006
Delegates at GoldenHorseshoe Biosciences Summit Catch The Future The coming life sciences revolution will reinvent health care, cause some national economies to boom and others to shrivel, and even change how factories look and operate, said keynote speaker Juan Enriquez, founding director of Harvard Business Schools (Boston, MA) Life Sciences Project.
|
|
August 08 2006
Millenium Biologics Restructures, Cuts Staff Kingston, Ont.-based Millenium Biologix Corp. has announced updates on product milestones and staff layoffs in an effort to reduce costs.
|
|
July 17 2006
Arius Moves Up at TSX Toronto-based Arius Research Inc. has graduated from the Toronto Venture Exchange to the Toronto Stock Exchange (TSX) (Toronto, ON).
|
|
July 05 2006
Medical Ventures Establishes U.S. Sales Force Medical Ventures Corp. (Richmond, BC) will be establishing a seven-person sales team by the second quarter of this year to market its Metricath® technology in the United States.
|
|
July 05 2006
Viron Raises $20M Viron Therapeutics Inc. (London, ON) has closed a $20-million US Series A round of financing.
|
|
June 19 2006
MDS Receives Top CRO Honours MDS Pharma Services (St. Laurent, QC), a division of MDS Inc., has earned the honour of top CRO in Europe through a survey conducted by Thomas CentreWatch, a news and information service focused on the clinical research industry.
|
|
May 31 2006
Mercuriades Awards Presented The Quebec Federation of Chambers of Commerce recently presented its 2006 Mercuriades Awards honouring Quebec-based private companies and organizations.
|
|
April 10 2006
Roche Plans $10M Expansion Laval, Que.-based Roche Diagnostics will be doubling its current head office by constructing a 26,230 square foot building.
|
|
March 22 2006
Lawsuit Settled, PCR and Thermal Cycler Sales Resume F. Hoffman-La Roche Ltd.'s (Basel, Switzerland) Molecular Diagnostics division and Applied Biosystems (Foster City, CA) have settled lawsuits originally filed against MJ Research, which was later acquired by Bio-Rad Laboratories Inc. (Hercules, CA).
|
|
March 22 2006
Applied Biosystems Expands Service Program Eleven companies and academic centres have joined Applied Biosystems' (Foster City, CA) Advanced Gene Expression Service Provider Program, expanding its reach throughout North America, Europe and Asia.
|
|
March 02 2006
BioAlberta Honours Companies Alberta's non-profit bio-industry association, BioAlberta, recently announced the winners of its 2005 BioAlberta Achievement Awards.
|
|
March 02 2006
MedMira Launches Diagnostic Division MedMira Inc. (Halifax, NS) has launched a new division that will focus on developing new diagnostic instruments.
|
|
February 06 2006
Nexia to Refocus on Oil and Gas Industry Montreal-based Nexia Biotechnologies Inc. has announced its intention to reorganize into an oil and gas company upon completion of an assessment of its corporate assets.
|
|
September 13 2005
Top 10 Attributes of the Emerging Biotech Superstar By Helga Long With the dearth of drug approvals in recent years, venture capital companies, big pharma firms and major biotech customers are all competing to create those biotech firms that can develop the drugs of the future.
|
|
September 13 2005
Canadian Biotech Companies: When and Where to Go Public By Cheryl Reicin and Daniel Miller Biotech companies have an insatiable need for cash. This means that, at some point, every biotech company considers whether or not to go public, and the thin venture capital market in Canada propels Canadian biotechs to consider this decision earlier than their U.S. counterparts.
|
|
August 08 2005
Balancing Act By Amber Lepage-Monette Complementary talents allow co-founders Donald McCaffrey and Dr. Norman Wong to walk the tight rope of transitioning Resverlogix into a new company
|
|
May 10 2005
Market Access Planning for Emerging Medical Technology: Health Technology Assessments By Jacqueline Csonka-Peeren Medical device manufacturers looking to commercialize emerging medical technology need to consider not only strategies for intellectual property protection and regulatory approval, but also for technology diffusion, or market access.
|
|
May 10 2005
The VC Vista Compiled by Deborah Komlos Industry Views on Canadian Biotech Financings for 2005-06
|
|
March 07 2005
Cost-saving Patent Strategies for Small and New Companies By Jennifer Jannuska and Lenni Carreiro The pressure to get patents has never been greater for small and new companies. Patents are the hard currency of research-based businesses. Investors want to see them, competitors have them and companies need them for licensing, leveraging, litigating and (occasionally) liquidating.
|
|
February 21 2005
BC Biotech Announces Winners British Columbia's non-profit biotechnology industry association, BC Biotech (Vancouver, BC) has announced the recipients of its 2005 BC Biotechnology Awards.
|
|
February 08 2005
Shifting the Balance By Kristine Archer Biotechs are Levelling the Playing Field in Biopartnering
|
|
January 17 2005
Regulatory Gauges Of Success By Deborah Komlos Filing With the FDA at Top of Canadian Firms' To-Do Lists
|
|
November 12 2004
COMMUNICATE for Success By Michelle Floyd ANSWERING TWO CRITICAL QUESTIONS WILL ENSURE YOU COMMUNICATE MORE EFFECTIVELY
|
|
November 01 2004
Marriage of Big Business and Big Science By Vincent Wright Coveted Synergy Award Granted to TRIUMF-MDS Nordion Partnership
|
|
October 06 2004
Seed MONEY By Patricia Nicholson EARLY FUNDING FOR BIOTECH ENTREPRENEURS
|
|
October 04 2004
BHRC Study Highlights Industry Needs Early last week, the Biotechnology Human Resources Council (BHRC) (Ottawa, ON) released the results of its Converging Science and Leadership - The Key to the Future study, which focuses on initiatives needed to push innovation toward commercialization.
|
|
September 20 2004
The IPO window: who will follow MethylGene? By Patricia Nicholson The fourth quarter of 2003 and the first half of 2004 saw a surge in biotech IPOs in the United States, and led to speculation that the Canadian IPO window might be opening for the first time in several years. The biotech industry turned its eyes to MethylGene Inc. (Montreal, QC), which completed a much-anticipated initial public offering in June.
|
|
August 23 2004
BIG BIOTECHS AND SMALL STARTUPS By Patricia Nicholson ERNST & YOUNG'S ANNUAL BIOTECH REPORT SHOWS A GULF BETWEEN PROSPEROUS AND PRECARIOUS COMPANIES IN CANADA
|
|
August 23 2004
The Impact of Ineffective Writing on Drug Development By Pamela E. Hurley, PhD MOST EVERYONE IN THE DRUG-DEVELOPMENT INDUSTRY KNOWS ABOUT THE DELAYS THAT OFTEN PLAGUE CLINICAL TRIALS, AND THEY'RE PROBABLY FAMILIAR WITH THE COST OF THESE DELAYS.
|
|
June 16 2004
The Virtues of Devices By Patricia Nicholson RIMON THERAPEUTICS PRESIDENT AND CEO MICHAEL MAY, PHD DEVELOPS THERAPEUTIC POLYMERS
|
|
June 16 2004
Beyond Basic Research By Amber Lepage-Monette Government agencies and venture capital firms look to strengthen commercialization funding
|
|
May 14 2004
Investor Relations: Great Expectations By Joanna Longo Senior executives of public companies have more options than ever to get their stories across to the investment community. Does that make the task easier? Unfortunately, with an increasing number of companies competing for capital, it is probably more difficult than ever to build your company's profile within the investment community.
|
|
May 03 2004
Commercialization Award Granted to ViRexx Edmonton, Alta.-based ViRexx Medical Corp. has received a $500,000 award to help further its clinical research.
|
|
April 19 2004
From Proof of Concept Commercialization By Shabbir T. Anik, PhD and Colin M. Minchom, PhD Biotech companies usually face significant time pressures to initiate clinical trials. Under these circumstances, it is important to select a contract service provider that has the ability to develop fast-into-human formulations for proof of concept studies.
|
|
March 16 2004
Coping with Crises By Suzanne Paschall Your web site as a crisis communications tool
The worst has happened. Your organization has been hit with a crisis, maybe of a magnitude you had never predicted. You go into your crisis communications and management mode - the one so carefully thought through in last years strategic planning retreat. |
|
March 08 2004
The Future of Pharma: Transforming the Supply Chain By Deborah Komlos For the pharmaceutical industry to achieve the type of financial performance it did in the 1990s and to meet challenges in the coming years, a radical re-appraisal of the supply chain model is needed.
|
|
February 09 2004
Forum Examines Life Science R&D Productivity Salvatore Salamone Life science researchers increasingly must identify, assimilate, interpret and pull together many more new sources of information to conduct their work. This is an enormous challenge that is only going to get more difficult as research efforts become more specialized, further compartmentalizing information into isolated silos.
|
|
February 02 2004
CIHR Releases Strategy Blueprint The strategic plan that will guide the activities of the Canadian Institutes of Health Research (CIHR) (Ottawa, ON) over the next five years was released on Jan. 20.
|
|
January 12 2004
The Regulation of Stem Cell Research in Canada By Jeffrey Graham, Tim McCunn and Andrew Loh In recent times there have been efforts to impose new requirements with respect to stem cell research. Essentially, stem cells are precursor cells - ones that can differentiate into more specialized cells when signalled to do so. The interest in stem cells lies in their ability to be cultured in a laboratory and directed to become specific types of cells or tissue that can be used to create genuine substitutes for damaged body parts.
|
|
December 01 2003
The Investor Presentation: Making the Perfect Pitch It's 9:00 a.m. Monday morning. An analyst and two investment bankers in tailored blue suits sit impatiently at your boardroom table. The PowerPoint projector bursts to life and your heart starts racing. It's show time! You have 20 minutes to convince them that your company is worthy of their time and investment.
|
|
October 01 2003
Demonstrating Value for Money of Biopharmaceuticals BY GEORGE W. TORRANCE, PhD AND DANIEL T. GRIMA, M.Sc Health economics, regulation and reimbursement worldwide
|
|
October 01 2003
Leadership Development BY MARIE LEGAULT A sound investment strategy for biotech companies
|
|
May 01 2003
Capital Markets Advice for Junior Public Biotech Companies BY LARRY JEREMIAS The how-tos for achieving institutional quality
In Canada, the dilemma facing many early stage companies looking to raise capital is that it is often necessary to become public first. The reality is that most biotech companies in Canada become public too early; either they are not ready to be public, but have little choice or they believe they have little choice. |
|
May 01 2003
Five Competencies for Managing Growth By Doug Treen, MBA, PhD Are you prepared to manage growth as your biotech company scales up to launch its new product? Managing growth requires a unique set of management skills, and scientific success in creating the product does not ensure success as a manager. Managing people to create growth depends on special competencies.
|
|
March 01 2003
Public Relations for Biotechnology Companies BY DOMINIC SICOTTE Luxury or necessity?
The expression "public relations" was first used by Thomas Jefferson, third president of the United States, back in 1802. Times have changed a great deal over the past two centuries. Because of increased business competition and the tremendous evolution of communications, public relations today are a key aspect of the healthy management of many businesses. |
|
January 02 2003
Is Your Patent Portfolio Ready for Due Diligence? By Micheline Gravelle Like death and taxes, due diligence on a biotechnology company's patent portfolio is a certainty. Few biotechnology companies can bring a product to market without receiving venture capital and/or partnering with a larger company. Any potential investor or partner will critically evaluate your patent portfolio before deciding whether or not to invest in, or partner with, your company.
|
|
January 01 2003
The Biotech Sector: Playing for Keeps BY ANDRÉ P. BOULET, PhD Growth potential in biotech despite market woes
Over the past year and a half, the financial markets have suffered not only from the World Trade Center tragedy and associated terrorist activities, but also from Wall Street scandals such as Enron, WorldCom, ImClone/Bristol-Myers Squibb and Merck-Medco among others. |
